Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objectives: To further characterize the beneficial impact of testosterone replacement therapy ( TRT ) on the association between mortality and hypogonadism ( HG ) in men with type 2 diabetes (T2 DM ), by determining, firstly, if changes in cardiovascular disease ( CVD ) risk factors after TRT play a role, secondly, whether the reduction in mortality is lost when TRT is discontinued and, finally, the presence of subgroups where benefit may be greater. Materials and Methods: We studied 857 men with T2 DM , screened for the BLAST randomized controlled trial, over 3.8 years of follow‐up. The men were stratified first by testosterone levels: group 1: total testosterone ( TT ) >12 nmol/L and free testosterone ( FT ) >0.25 nmol/L; Group 2: TT ≤12 nmol/L or FT ≤0.25 nmol/L. Group 2 was further stratified into those not on TRT (Group 2a) and those on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression. Results: We found that TRT was not associated with improvements in CVD risk factors. CVD risk factors (baseline and changes during follow‐up) were not associated with mortality. Men in Group 1 and Group 2b were found to have lower mortality (reference: Group 2a), even with CVD risk factors included in the regression models. Mortality was lower in men in Group 2b1 (6.2%) and Group 2b2 (0%) compared with those in Group 2a (16.9%). The lower mortality associated with Group 1 and Group 2b was observed primarily in older (>64.6 years) and less overweight (≤93.8 kg) men. Conclusions: The benefits associated with normal testosterone levels and TRT (even after discontinuation) do not appear to be related to improvements in the CVD risk factors studied. In view of TRT having greater impact in men of lower weight, better outcomes may be achieved with concurrent TRT and weight reduction programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
JBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
Corona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
Waist Circumference and Testosterone Levels in Community Dwelling Men. The Tromsø Study
Svartberg, J., von Mühlen, D., Sundsfjord, J., & Jorde, R. (2004) · European Journal of Epidemiology · doi:10.1023/b:ejep.0000036809.30558.8f · Cited by 229
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182
Self-citationHackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168
Self-citationSaboor Aftab, S. A., Kumar, S., & Barber, T. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12092 · Cited by 157
Ponce, O. J., Spencer-Bonilla, G., Alvarez-Villalobos, N., Serrano, V., Singh-Ospina, N., Rodriguez-Gutierrez, R., Salcido-Montenegro, A., Benkhadra, R., Prokop, L. J., Bhasin, S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00404 · Cited by 148
Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12664 · Cited by 139
Ng Tang Fui, M., Hoermann, R., Prendergast, L. A., Zajac, J. D., & Grossmann, M. (2017) · International Journal of Obesity · doi:10.1038/ijo.2016.242 · Cited by 40
Cited by
Wittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30367-3 · Cited by 362
Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T. (2019) · Diabetes Care · doi:10.2337/dc18-2388 · Cited by 164
Haider, K. S., Haider, A., Saad, F., Doros, G., Hanefeld, M., Dhindsa, S., Dandona, P., & Traish, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14122 · Cited by 82
Metadata
- Authors
- Hackett, G., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2018-10-16
- Volume
- 123
- Issue
- 3
- Pages
- 519-529
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2891885274
- Cited by
- 43
- References
- 14
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.